Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21,277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes.
Huang Y, Durall RT, Luong NM, Hertzler HJ, Huang J, Gokhale PC, Leeper BA, Persky NS, Root DE, Anekal PV, Montero Llopis PDLM, David CN, Kutok JL, Raimondi A, Saluja K, Luo J, Zahnow CA, Adane B, Stegmaier K, Hawkins CE, Ponne C, Le Q, Shapiro GI, Lemieux ME, Eagen KP, French CA. Huang Y, et al. Among authors: luo j. Cancer Res. 2023 Dec 1;83(23):3956-3973. doi: 10.1158/0008-5472.CAN-23-1475. Cancer Res. 2023. PMID: 37747726
The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma.
Durall RT, Huang J, Wojenski L, Huang Y, Gokhale PC, Leeper BA, Nash JO, Ballester PL, Davidson S, Shlien A, Sotirakis E, Bertaux F, Dubus V, Luo J, Wu CJ, Keskin DB, Eagen KP, Shapiro GI, French CA. Durall RT, et al. Among authors: luo j. Cancer Res. 2023 Dec 1;83(23):3846-3860. doi: 10.1158/0008-5472.CAN-23-2545. Cancer Res. 2023. PMID: 37819236 Free PMC article.
Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
Luo J, Sanchez M, Lee E, Hertzler H, Luong N, Mazzola E, Finstein B, Tamen R, Brisbane G, Nguyen T, Paik PK, Chaft JE, Cheng ML, Khalil H, Piha-Paul SA, Sholl LM, Nishino M, Jänne PA, DuBois SG, Hanna GJ, Shapiro GI, French CA. Luo J, et al. J Thorac Oncol. 2024 May;19(5):829-838. doi: 10.1016/j.jtho.2023.12.022. Epub 2023 Dec 27. J Thorac Oncol. 2024. PMID: 38154515
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Rizvi H, Elkrief A, Luo J, Alessi JV, Pecci F, Lamberti G, Di Federico A, Hong L, Zhang J, Heymach JV, Gibbons DL, Plodkowski AJ, Ravichandran V, Donoghue MTA, Vanderbilt C, Ladanyi M, Rudin CM, Kris MG, Riely GJ, Chaft JE, Hellmann MD, Vokes NI, Awad MM, Schoenfeld AJ. Thummalapalli R, et al. Among authors: luo j. Clin Cancer Res. 2023 Nov 1;29(21):4408-4418. doi: 10.1158/1078-0432.CCR-23-1207. Clin Cancer Res. 2023. PMID: 37432985 Free PMC article.
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.
Luo J, Martucci VL, Quandt Z, Groha S, Murray MH, Lovly CM, Rizvi H, Egger JV, Plodkowski AJ, Abu-Akeel M, Schulze I, Merghoub T, Cardenas E, Huntsman S, Li M, Hu D, Gubens MA, Gusev A, Aldrich MC, Hellmann MD, Ziv E. Luo J, et al. Clin Cancer Res. 2021 Sep 15;27(18):5131-5140. doi: 10.1158/1078-0432.CCR-21-0921. Epub 2021 Jul 8. Clin Cancer Res. 2021. PMID: 34244291 Free PMC article.
Safety of image guided research biopsies in patients with thoracic malignancies.
Soosman SK, Schenker MP, Mazzola E, Voligny E, Smokovich A, Bay C, Nguyen T, Michael K, Jänne PA, Rabin M, Glazer DI, Johnson BE, Luo J. Soosman SK, et al. Among authors: luo j. Lung Cancer. 2022 Nov;173:53-57. doi: 10.1016/j.lungcan.2022.08.024. Epub 2022 Sep 17. Lung Cancer. 2022. PMID: 36152477
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.
Alessi JV, Wang X, Elkrief A, Ricciuti B, Li YY, Gupta H, Spurr LF, Rizvi H, Luo J, Pecci F, Lamberti G, Recondo G, Venkatraman D, Di Federico A, Gandhi MM, Vaz VR, Nishino M, Sholl LM, Cherniack AD, Ladanyi M, Price A, Richards AL, Donoghue M, Lindsay J, Sharma B, Turner MM, Pfaff KL, Felt KD, Rodig SJ, Lin X, Meyerson ML, Johnson BE, Christiani DC, Schoenfeld AJ, Awad MM. Alessi JV, et al. Among authors: luo j. J Thorac Oncol. 2023 Nov;18(11):1524-1537. doi: 10.1016/j.jtho.2023.05.019. Epub 2023 May 27. J Thorac Oncol. 2023. PMID: 37247843 Free PMC article.
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
Alessi JV, Ricciuti B, Jiménez-Aguilar E, Hong F, Wei Z, Nishino M, Plodkowski AJ, Sawan P, Luo J, Rizvi H, Carter BW, Heymach JV, Altan M, Hellmann M, Awad M. Alessi JV, et al. Among authors: luo j. J Immunother Cancer. 2020 Aug;8(2):e001007. doi: 10.1136/jitc-2020-001007. J Immunother Cancer. 2020. PMID: 32753547 Free PMC article.
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade.
Arbour KC, Luu AT, Luo J, Rizvi H, Plodkowski AJ, Sakhi M, Huang KB, Digumarthy SR, Ginsberg MS, Girshman J, Kris MG, Riely GJ, Yala A, Gainor JF, Barzilay R, Hellmann MD. Arbour KC, et al. Among authors: luo j. Cancer Discov. 2021 Jan;11(1):59-67. doi: 10.1158/2159-8290.CD-20-0419. Epub 2020 Sep 21. Cancer Discov. 2021. PMID: 32958579 Free PMC article.
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.
Memon D, Schoenfeld AJ, Ye D, Fromm G, Rizvi H, Zhang X, Keddar MR, Mathew D, Yoo KJ, Qiu J, Lihm J, Miriyala J, Sauter JL, Luo J, Chow A, Bhanot UK, McCarthy C, Vanderbilt CM, Liu C, Abu-Akeel M, Plodkowski AJ, McGranahan N, Łuksza M, Greenbaum BD, Merghoub T, Achour I, Barrett JC, Stewart R, Beltrao P, Schreiber TH, Minn AJ, Miller ML, Hellmann MD. Memon D, et al. Among authors: luo j. Cancer Cell. 2024 Feb 12;42(2):209-224.e9. doi: 10.1016/j.ccell.2023.12.013. Epub 2024 Jan 11. Cancer Cell. 2024. PMID: 38215748 Free article.
21,277 results
You have reached the last available page of results. Please see the User Guide for more information.